Jazz Pharmaceuticals plc (JAZZ) · Aug 31, 2026 · New debt

Jazz Pharmaceuticals closes $1.25B notes deal, trading cheap capital for dilution risk

$1.25B notes issued — $1.25B principal; $1.2264B net proceeds after full option exercise

Jazz completed its upsized exchangeable-note deal at a low 1.875% coupon, funding buybacks while creating potential future share dilution.

The concurrent buyback partially offsets the equity overhang but uses cash and reduces remaining authorization. Jazz repurchased approximately $225 million of shares at $249.29, leaving roughly $1.001 billion of gross financing proceeds before other corporate uses; the filing explicitly says the repurchase reduced the remaining amount authorized under its existing buyback program. (Item 1.01) Net versus expectations, this is best classified as a completed, already-known capital-structure transaction: attractive low-cost funding and an immediate buyback, balanced by higher debt and potential future dilution.

What to watch next

First interest payment, March 15, 2027

Original filing on SEC EDGAR

More Jazz Pharmaceuticals plc news

Jazz Pharmaceuticals closes $1.25B notes deal, trading cheap capital for dilution risk | JAZZ Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.